- Home
- LYEL vs HQL Comparison
LYEL vs HQL Comparison
Compare LYEL & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LYEL | HQL |
|---|---|---|
| Founded | 2018 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 492.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LYEL | HQL |
|---|---|---|
| Price | $22.27 | $15.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 95.9K | ★ 135.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $61,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.66 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $10.55 |
| 52 Week High | $45.00 | $17.80 |
Technical Indicators
Market Signals| Indicator | LYEL | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 33.67 |
| Support Level | $21.27 | $15.67 |
| Resistance Level | $27.30 | $17.51 |
| Average True Range (ATR) | 2.12 | 0.30 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 26.16 | 4.64 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.